Table 2.

Main features of patients positive to parvovirus B19-DNA in bronchoalveolar lavage.

Sex/age	Underlying condition	Immune status	Clinical diagnosis	Mortality	Viral load (GEq/ml)	Other pathogens
F/59	Haematological malignancy on chemotherapy	Compromised	Respiratory insufficiency	No	705	Human herpesvirus-6, human rhinovirus
M/59	Haematological malignancy on chemotherapy	Compromised	Pneumonia, sepsis	Yes (at 3 days)	<125	Epstein–Barr virus, bacteria
F/78	Acute respiratory condition	Competent	Respiratory insufficiency	Yes (at 26 days)	<125	No
M/38	Lung transplantation	Compromised	Follow-up bronchoscopy	No	370	Human cytomegalovirus
M/60	Acute respiratory condition	Competent	Respiratory insufficiency	Yes (at 1 day)	<125	Human rhinovirus
M/78	Acute respiratory condition	Competent	Respiratory insufficiency	No	<125	Human herpesvirus-7, human rhinovirus
F/43	Lung transplantation	Compromised	Follow-up bronchoscopy	No	12943	Human cytomegalovirus, human herpesvirus-7

GEq, genome equivalents.